Fox Run Management L.L.C. Acquires Shares of 18,526 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Fox Run Management L.L.C. bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 18,526 shares of the company’s stock, valued at approximately $688,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMPH. Smartleaf Asset Management LLC increased its holdings in Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after buying an additional 493 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after purchasing an additional 871 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the period. TD Private Client Wealth LLC lifted its stake in Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after purchasing an additional 388 shares during the last quarter. Finally, KBC Group NV grew its holdings in Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after purchasing an additional 650 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH opened at $28.46 on Tuesday. The stock’s 50-day moving average is $31.72 and its 200 day moving average is $40.36. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of 9.49, a P/E/G ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a 1-year low of $25.89 and a 1-year high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Analysts Set New Price Targets

Separately, Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Friday.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.